BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T153941
CREATED:20240522T154559Z
LAST-MODIFIED:20240829T193857Z
UID:39134-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:6th Macrophage-Directed Therapies Summit
DESCRIPTION:Learning From the Past & Spearheading Macrophage Clinical Acceleration \nThe 6th Macrophage-Directed Therapies Summit is uniting 60+ biopharma and academia leaders across R&D\, Discovery\, Biology\, Translational\, and Clinical Development fields for invaluable networking and insights into all facets of macrophage-directed therapies. \nGrab your Full Agenda – https://ter.li/nqf2qd \nDespite toxicity concerns for CD47 targets in 2023\, the macrophage community persists in exploring innovative targets. Their determination to unveil new data showcasing safety and proof of concept remains stronger than ever\, revitalizing momentum in this highly promising industry. \nThis October\, you could meet leading experts from Verseau Therapeutics\, Inceptor Bio\, Carisma Therapeutics\, Elpiscience Biopharmaceuticals\, John Hopkins School of Medicine\, Resolution Therapeutics\, and more\, offering exclusive insights into their winning strategies for staying ahead of the curve in the years ahead. \nKey Highlights: \n\nTackling challenges in delivery\, administration\, animal model selection\, reprogramming\, manufacturing\, and more to optimize choices\nExploring indications for extending beyond oncology to autoimmunity\, inflammation\, neurodegenerative diseases\, and beyond\nAssessing the evolving macrophage-therapeutics landscape to uncover innovative targets and the latest data\n\nRegister Here for the Best Savings – https://ter.li/o22pxt
URL:http://www.pharmajournalist.com/event/6th-macrophage-directed-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241001
DTEND;VALUE=DATE:20241004
DTSTAMP:20260515T153941
CREATED:20240530T075147Z
LAST-MODIFIED:20240719T125600Z
UID:39187-1727740800-1727999999@www.pharmajournalist.com
SUMMARY:4th iPSC Drug Development & Manufacturing Summit
DESCRIPTION:With Kenai Therapeutics emerging from stealth with an $82 Million Series A funding round\, 2024 has started strong for iPSC drug developers looking to showcase the potential of their pipelines ahead of the next wave of investment. Introducing the 4th iPSC Drug Development & Manufacturing Summit\, your longest standing and definitive iPSC focused platform. \nNo iPSC stone will be left unturned\, as key industry experts including Kenai Therapeutics\, Cytovia Therapeutics\, Aspen Neuroscience\, NIST and many more\, unite under one roof to transform the future of iPSC cell therapies. For the first time in 4 years\, uniting R&D teams\, manufacturing experts and business leaders\, across 2 tracks of content for 3-days of cutting edge data presentations and strategic cross-functional discussions. Take a look at the full session details today. \nWith all this and more\, don’t miss this golden opportunity to help you and your entire team stay at the forefront of the iPSC cell therapy revolution!
URL:http://www.pharmajournalist.com/event/4th-ipsc-drug-development-manufacturing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR